HK Stock Market Move | Some concept stocks of innovative drugs have risen. In the first quarter, the total amount of innovative drugs in China exceeded 60 billion US dollars. The performance of pharmaceutical companies throughout the year is impressive.

Some innovative drug concept stocks rose, as of the time of writing, AKESO (09926) rose by 6.65% to HK$134.8; REMEGEN (09995) rose by 6.32% to HK$100.1; InnoCare Pharma (09969) rose by 4.42% to HK$13.69; INNOVENT BIO (01801) rose by 1.35% to HK$86.65. According to reports from CCTV, the National Medical Products Administration announced that in the first three months of this year, the total amount of foreign authorized transactions for innovative drugs in China exceeded $60 billion, close to half of the full year of 2025; the latest statistics from the National Medical Products Administration show that as of March 27, 2026, China has approved 10 new innovative drugs, including 2 imported and 8 domestic. China's innovative drugs have made historic breakthroughs, maintaining good development momentum and potential. It is worth noting that as of March 29, more than 70 biopharmaceutical companies have released their 2025 performance. Among them, 61 companies were profitable, accounting for nearly 90%; 29 companies achieved year-on-year growth in net profit attributable to the mother (excluding turning losses), with 7 companies achieving doubled performance. In addition, REMEGEN, InnoCare Pharma, DIGIHUMAN, and other companies are expected to turn losses into profits, while companies such as MENGYE Pharmaceutical, JUNSHI BIO, and MAIWEI BIOLOGICAL have achieved reduced losses year-on-year.